Robert A. Newman
About
In The Last Decade
Robert A. Newman
299 papers receiving 17.6k citations
Hit Papers
Peers
Comparison fields: 5 of 173
- Molecular Biology 7.5k
- Molecular Medicine 4.3k
- Oncology 2.7k
- Pharmacology 2.6k
- Nutrition and Dietetics 1.8k
Countries citing papers authored by Robert A. Newman
This map shows the geographic impact of Robert A. Newman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Newman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Newman more than expected).
Fields of papers citing papers by Robert A. Newman
This network shows the impact of papers produced by Robert A. Newman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Newman. The network helps show where Robert A. Newman may publish in the future.
Co-authorship network of co-authors of Robert A. Newman
This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Newman. A scholar is included among the top collaborators of Robert A. Newman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Newman. Robert A. Newman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 4 | |
| 4 | 21 | |
| 5 | 39 | |
| 6 | 46 | |
| 7 | 70 | |
| 8 | 39 | |
| 9 | 114 | |
| 10 | Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. | 20 |
| 11 | The dual PPARα/γ ligand TZD18 inhibits cell growth and induces apoptosis in human Bcr-Abl positive CML cell lines >in vitro | 1 |
| 12 | Zyflamend®-mediated inhibition of human prostate cancer PC3 cell proliferation: Effects on 12-LOX and Rb protein phosphorylation . | 1 |
| 13 | An LC/MS/MS based method to analyze tissue eicosanoids: Application to EPA-mediated alteration of prostaglandin metabolism | 1 |
| 14 | 56 | |
| 15 | Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. | 272 |
| 16 | 17 | |
| 17 | Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA. | 3 |
| 18 | In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. | 6 |
| 19 | Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. | 25 |
| 20 | 30 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.